<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820169</url>
  </required_header>
  <id_info>
    <org_study_id>RD001551</org_study_id>
    <nct_id>NCT01820169</nct_id>
  </id_info>
  <brief_title>Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG</brief_title>
  <official_title>Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Japan: National organization Hospital Kyoto Medical Center</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is to determine if the use of structured testing, which is a blood
      glucose monitoring,  via the Accu-Chek 360° View blood glucose analysis tool has a positive
      effect on the subjects overall glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Improvement in HbA1c in 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Comparison with historical control in HbA1c change.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Change in blood gulucose.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Change in BMI.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Occurance of sever hypoglycemia.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Doctor's opinion for Accu-Chek 360° View.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>;Accu-Chek Compact Plus LCM bulk Japan</intervention_name>
    <description>HbA1c would be changed by more careful control in blood glucose with SMBG.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age:= and &gt;20 years.   2. Intend to paticipate in this study after education of
        structured testing.   3.HbA1c:= and &gt;7.5% in the recect 2 months.

        Exclusion Criteria:

        1.Pregancy.   2. Heavy complication   3. judged unsuitable by doctor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Naoki Sakane</last_name>
    <role>Principal Investigator</role>
    <affiliation>National organization Hospital Kyoto Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
